TMTPOST — Pinshan Biotechnology (Shanghai) Co Ltd completed a Series A financing round of nearly 100 million RMB ($14 million), led by Yifeng Capital with participation from Lengshanxi Capital, Xunshang Venture Capital, and Ruixia Investment. Proceeds will support ongoing R&D and industrialization of core products including high-end filtration membranes and chromatography fillers, alongside expanded commercialization efforts in the biopharmaceutical consumables sector. Domestic innovation in bioprocessing materials is gaining momentum on the Chinese mainland as local drugmakers seek to reduce reliance on imported purification technologies amid rising production scales and cost pressures in the biologics pipeline. For specialized suppliers like Pinshan Biotech, fresh capital injections enable faster scaling of critical consumables that underpin quality and efficiency gains across the industry’s manufacturing expansion.